Arjunolic acid, a functionally rich chiral triterpenoid with a rigid pentacyclic backbone, has the potential to be used as a structural framework for the design of molecular receptors and supramolecular architectures. The design and synthesis of the first arjunolic acid-derived 18-crown-6 and its binding studies with metal and tert-butylammonium ions are reported.
No takes yet. Share an insight, caveat, or question.
Bag et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: